BlackRock Amends Krystal Biotech Stake as of Dec 31, 2023
Ticker: KRYS · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1711279
| Field | Detail |
|---|---|
| Company | Krystal Biotech, Inc. (KRYS) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, holding-update
TL;DR
**BlackRock updated its Krystal Biotech holdings, showing continued institutional interest.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in Krystal Biotech, Inc. as of December 31, 2023. This amendment, the third for BlackRock, indicates a change in their beneficial ownership of Krystal Biotech's Common Stock. For investors, this filing shows that a major institutional investor like BlackRock continues to hold a significant position in Krystal Biotech, which can be seen as a vote of confidence in the company's long-term prospects, potentially influencing other investors' perceptions and the stock's stability.
Why It Matters
This filing confirms BlackRock's continued significant institutional ownership in Krystal Biotech, signaling their ongoing interest and belief in the company's value, which can reassure current and potential investors.
Risk Assessment
Risk Level: low — This filing is a routine update from a major institutional investor and does not indicate any immediate significant risk to the company or its stock.
Analyst Insight
A smart investor would note BlackRock's continued presence as a long-term holder, but also research the specific percentage of ownership (which is not detailed in this excerpt) to understand the full extent of their commitment and its potential impact on Krystal Biotech's stock.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person filing the SC 13G/A
- Krystal Biotech, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event which requires the filing of this statement
- January 29, 2024 (date) — the filing date of the SC 13G/A
- 501147102 (number) — the CUSIP number for Krystal Biotech, Inc. Common Stock
Forward-Looking Statements
- BlackRock will maintain a significant stake in Krystal Biotech for the foreseeable future. (BlackRock, Inc.) — medium confidence, target: December 31, 2024
- Krystal Biotech's stock price will experience minor stability due to continued institutional holding. (Krystal Biotech, Inc.) — low confidence, target: June 30, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a major asset management firm.
What is the subject company whose securities are being reported?
The subject company is Krystal Biotech, Inc., identified by the CIK 0001711279 and CUSIP 501147102.
What is the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' is December 31, 2023.
Which rule under the Securities Exchange Act of 1934 is this Schedule 13G filed pursuant to?
This Schedule 13G is filed pursuant to Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the checked box [X].
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding Krystal Biotech, Inc. (KRYS).